Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Micromass was a pioneering developer and manufacturer of mass spectrometry (MS) systems, specifically recognized for advancing liquid chromatography-mass spectrometry (LC-MS) technologies. Based in Manchester, UK, the company provided critical analytical tools for the pharmaceutical, biotechnology, and clinical research industries. Following its acquisition by Waters Corporation in 1997, Micromass's technology became the foundation of Waters' mass spectrometry business, driving significant advancements in proteomics, metabolomics, and drug metabolism studies. The company's innovations, such as the development of the triple quadrupole and time-of-flight (ToF) systems, were instrumental in the growth of modern bioanalytical chemistry. Today, its legacy continues through the Waters mass spectrometry portfolio, which remains a standard in laboratories worldwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Micromass.